Neuroprotective role of erythropoietin in neonates
Author:
- 8 September 2012
- journal article
- research article
- Published by Taylor & Francis in The Journal of Maternal-Fetal & Neonatal Medicine
- Vol. 25 (sup4) , 97-99
Abstract
This review summarizes target populations of neonates for which erythropoietin (Epo) neuroprotective therapy might be of benefit, and the mechanisms by which Epo functions as a neuroprotective agent. Potential risks of Epo are reviewed. Finally, the progression of Epo neuroprotection from preclinical studies to translational studies is discussed.Keywords
This publication has 19 references indexed in Scilit:
- National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implicationsThe Lancet, 2012
- Systemic inflammation disrupts the developmental program of white matterAnnals of Neurology, 2011
- Enhanced Oligodendrogenesis and Recovery of Neurological Function by Erythropoietin After Neonatal Hypoxic/Ischemic Brain InjuryStroke, 2010
- The Encephalopathy of Prematurity—Brain Injury and Impaired Brain Development Inextricably IntertwinedSeminars in Pediatric Neurology, 2009
- Microarray Analysis of High-Dose Recombinant Erythropoietin Treatment of Unilateral Brain Injury in Neonatal Mouse HippocampusPediatric Research, 2009
- Brain injury in premature infants: a complex amalgam of destructive and developmental disturbancesThe Lancet Neurology, 2009
- Neuroprotective properties and mechanisms of erythropoietin in in vitro and in vivo experimental models for hypoxia/ischemiaBrain Research Reviews, 2008
- Cost of Hospitalization for Preterm and Low Birth Weight Infants in the United StatesPediatrics, 2007
- Neonatal Hypoxia/Ischemia Is Associated With Decreased Inflammatory Mediators After Erythropoietin AdministrationStroke, 2005
- Neurologic and Developmental Disability at Six Years of Age after Extremely Preterm BirthNew England Journal of Medicine, 2005